多发性硬化症市场规模、份额和成长分析（按药物类别、诊断、给药途径、分销管道、最终用户和地区）—2025-2032 年产业预测

2023 年全球多发性硬化症市场规模价值 260.4 亿美元，预计将从 2024 年的 266.4 亿美元增长到 2032 年的 319.5 亿美元，预测期内（2025-2032 年）的复合年增长率为 2.3%。

由于多发性硬化症 (MS) 盛行率不断上升以及对研发的重视程度不断提高，预计该疾病治疗市场将经历显着增长。多发性硬化症的特征是免疫介导的中枢神经系统损害，引起疲劳、麻木和认知障碍等症状。单株抗体在治疗中发挥着至关重要的作用，目前正在进行临床试验以开发创新治疗方法。全球对人源化单株抗体和免疫抑制剂的需求正在激增，反映出有效治疗 MS 的紧迫性。製药公司和学术机构之间的合作研究协议进一步活性化了市场活动，将 MS 药物开发定位为医疗保健领域投资和创新的主要领域。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

多发性硬化症市场规模（按药物类别和复合年增长率） (2025-2032)

• 市场概况
• 免疫调节药物
• 免疫抑制剂
• 干扰素
• 其他的

多发性硬化症市场规模（按诊断和复合年增长率）（2025-2032）

• 市场概况
• 磁振造影（MRI）
• 简单电刺激试验
• 腰椎穿刺
• 其他的

多发性硬化症市场规模（依给药途径及复合年增长率）（2025-2032）

• 市场概况
• 口服
• 肠外
• 其他的

多发性硬化症市场规模（按分销管道和复合年增长率） (2025-2032)

• 市场概况
• 医院药房
• 零售药局
• 网路药局
• 其他的

多发性硬化症市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概况
• 医院
• 专科门诊
• 居家护理
• 其他的

多发性硬化症市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Biogen Inc.（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Novartis AG（Switzerland）
• Roche Holding AG（Switzerland）
• Key Developments
• Merck KGaA（Germany）
• Bayer AG（Germany）
• Johnson & Johnson（United States）
• AbbVie Inc.（United States）
• TG Therapeutics, Inc.（United States）
• Acorda Therapeutics, Inc.（United States）
• Alkermes plc（Ireland）
• H. Lundbeck A/S（Denmark）
• Eli Lilly and Company（United States）
• GlaxoSmithKline plc（United Kingdom）
• Pfizer Inc.（United States）
• Celgene Corporation（United States）
• Mallinckrodt Pharmaceuticals（United Kingdom）
• UCB SA（Belgium）
• Orion Corporation（Finland）

结论和建议

Global Multiple Sclerosis Market size was valued at USD 26.04 billion in 2023 and is poised to grow from USD 26.64 billion in 2024 to USD 31.95 billion by 2032, growing at a CAGR of 2.3% during the forecast period (2025-2032).

The market for multiple sclerosis (MS) treatments is poised for significant growth, driven by the increasing prevalence of the disease and a heightened focus on research and development. MS, characterized by immune-mediated damage to the central nervous system, leads to symptoms like fatigue, numbness, and cognitive issues. Monoclonal antibodies play a pivotal role in treatment, with ongoing clinical trials aimed at developing innovative therapies. The demand for humanized monoclonal antibodies and immunosuppressive drugs is surging globally, reflecting the urgency for effective MS management. Collaborative research agreements between pharmaceutical companies and academic institutions have further intensified market activity, positioning MS medication development as a key area of investment and innovation in the healthcare sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiple Sclerosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multiple Sclerosis Market Segments Analysis

Global Multiple Sclerosis Market is segmented by Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users and Region. Based on Drug Class, the market is segmented into Immunomodulators, Immunosuppressants, Interferons and Others. Based on Diagnosis, the market is segmented into Magnetic Resonance Imaging (MRI), Simple Electrical Stimulation Tests, Lumbar Puncture and Others. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Multiple Sclerosis Market

The rising prevalence of multiple sclerosis is a key factor fueling the growth of the global market. This condition is divided into four distinct types: relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS), and progressive-relapsing MS (PRMS). The high incidence rates associated with these forms are likely to significantly influence market trends and dynamics throughout the forecast period. As more individuals are diagnosed and require effective treatments, the demand for innovative therapies and medical solutions is expected to increase, ultimately driving the overall expansion of the multiple sclerosis market on a global scale.

Restraints in the Global Multiple Sclerosis Market

Conversely, the Global Multiple Sclerosis market is likely to experience constraints that could hinder its growth. The exorbitant expense associated with the treatment of multiple sclerosis poses a significant barrier to market expansion. Additionally, developing countries are grappling with a shortage of trained professionals and insufficient healthcare infrastructure, further complicating access to treatment. The COVID-19 pandemic has also led to a decline in clinical visits, and a general lack of awareness among the public regarding the disease can impede market progress. These factors collectively are expected to restrain the market's growth throughout the forecast period from 2022 to 2029.

Market Trends of the Global Multiple Sclerosis Market

The global Multiple Sclerosis (MS) market is witnessing a robust trend driven by significant investments in research and development (R&D) aimed at innovative treatments. Pharmaceutical companies, including emerging players like Pipeline Therapeutics, are increasingly focusing on advanced therapeutic candidates, such as PIPE-307, a selective M1 receptor antagonist currently undergoing clinical trials. The proliferation of research collaborations between pharmaceutical firms and academic institutions further enhances the landscape, spurring growth. As companies diversify their pipelines with novel treatment options, this renewed emphasis on R&D is poised to catalyze market expansion, providing patients with more effective treatment choices and improving overall outcomes in MS management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Multiple Sclerosis Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Immunomodulators
• Immunosuppressants
• Interferons
• Others

Global Multiple Sclerosis Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Magnetic Resonance Imaging (MRI)
• Simple Electrical Stimulation Tests
• Lumbar Puncture
• Others

Global Multiple Sclerosis Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Others

Global Multiple Sclerosis Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Multiple Sclerosis Market Size by End-Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Multiple Sclerosis Market Size & CAGR (2025-2032)

• North America (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
  • US
  • Canada
• Europe (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
• Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TG Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acorda Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkermes plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orion Corporation (Finland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations